CA-BATTERY-SHOW/EV-TECH
The Battery Show & EV Tech Europe Digital Days , a three-day digital event, strategically scheduled for 18-20 May to connect and educate industry professionals during a time of immense disruption via technical sessions, panels, networking opportunities, and digital sourcing, today announced the second raft of speakers confirmed to address the advanced battery and hybrid & electric vehicle (H/EV) tech community. Executives and senior-level experts from 3M, EnBW, McLaren Applied, Punch Powertrain, Renault, among many others, will present novel solutions and lead technical demonstrations that address the industry's leading challenges. The online conference will run adjacent to the digital exhibition floor that features hundreds of leading companies including Parker/LORD, Siemens, and TE Connectivity.
Registration for the digital conference and exhibition is open to attendees and press:
As the effects of the ongoing COVID-19 pandemic continue to impact grid storage, battery materials, battery-powered electric vehicles, and manufacturer supply chains, the European region is presented with unprecedented stressors amid exceptional market acceleration. Speaking to the importance and timeliness of the event, James Frith, Head of Energy Storage at Bloomberg New Energy Finance and chair of the keynote panel “Meeting Demand for EV Battery Production in Europe; The Rise of the Giga Factory,” said: "The European battery manufacturing industry has been turned on its head over the last three years, going from almost non-existent to the second largest market globally. The Digital Days event will be the perfect opportunity to find out how the companies at the heart of this change envisage the next decade."
"At the rate the advanced battery and H/EV tech sectors are progressing in the European region and the number of obstacles that require an immediate solution, we felt it was critical to orchestrate industry connection before our next in-person event in November," said Rob Shelton, group event director, The Battery Show & EV Tech Europe Digital Days, Informa Markets. "The level of support for the upcoming digital event permeates all corners of the industry and is a clear indicator of the battery and H/EV tech market's fortitude and future advancement."
Featured conference content includes:
Tuesday 18 May
EV Forecasts: 2020 Summary of European EV Market Expansion and its Implications on Battery Demand
Speaker: Viktor Irle, Co-Founder & Market Analyst, EV Volumes
Latest Developments in EV Architectures: Determining the Optimum Level of Hybridization versus Societal, Environmental, and Economic Benefits
Speaker: Marcin Seredynski, Head of Innovation and Research, E-Bus Competence Centre
Race to Road Debate: Examining Formula E & Hyper Car Architectures and How they Can be Adapted for the Mass Market EV
Moderator: Luke Gear, Technology Analyst, IDTechEx
- Angus Lyon, Director, Rockfort Engineering
- Yu Merla, Principal Engineer - Advanced Battery Projects, Williams Advanced Engineering
- Wasim Sarwar, Head of Research and Advanced Engineering, Rimac Automobil
Wednesday 19 May
EV Technical Session: The Role of Electric Vehicles in the Energy Transition
Speaker: Jeremy Parkes, Global Business Lead - Electric Vehicles, DNV
Keynote (Open to All) – Leaders Panel: Meeting Demand for EV Battery Production in Europe; the Rise of the Giga Factory
Moderator: James Frith, Senior Energy Storage Analyst, Bloomberg New Energy Finance
- Benoit Lemaignan, CEO, Verkor
- Kai-Uwe Wollenhaupt, President Europe & Vice President, SVOLT Energy Technology Company Ltd
- Sebastian Wolf, Sr Director EU Operations and Managing Director, Farasis Energy Europe
- Gery Bonduelle, SVP Sales, Freyr
- Allan Paterson, CTO, Britishvolt
Electric Motor Development: Faster Charging, Higher Efficiency, Longer Range: The next Step in Electrification
Steve Lambert, Head of Electrification, McLaren Applied
Electric Powertrain: Developing High-Speed Electric Drive Unit for the Next Generation
Speaker: Henrik Dhejne, Product Line Manager - Passenger Car Transmissions, electrified Transmission & e-Axle, AVL
Thursday 20 May
EV Technical Session: State of the art Electric Track Drive for Medium & Heavy-Duty Machines
Speaker: Massimo Palomba, Global Sales Manager E-Mobility, Bonfiglioli Mobility & Wind Industries, Bonfiglioli Spa
EV Technical Session: HEV Battery Design; Should it be for Second Life or Easy to Recycle?
Speaker: Paweł Swoboda, Business Development Manager, BMZ Poland
Electric Buses: If 70% Of EV Cost is in The Battery… How Can You Reduce the Cost of Electrification?
Speaker: Manos Polioudis, Head of Powertrain Engineering, Arrival
For the full The Battery Show & EV Tech Europe Digital Days conference agenda, please visit here .
Follow The Battery Show & EV Tech Europe Digital Days on social media: #TheBatteryShow
About Informa Markets – Engineering:
Informa Markets' Engineering portfolio is the leading B2B event producer, publisher, and digital media business for the world's $3-trillion advanced, technology-based manufacturing industry. Our print and electronic products deliver trusted information to the engineering market and leverage our proprietary 1.3-million-name database to connect suppliers with buyers and purchase influencers. We produce more than 50 events and conferences in a dozen countries, connecting manufacturing professionals from around the globe. The Engineering portfolio is organized by Informa, the world's leading exhibitions organizer that brings a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit www.informamarkets.com .
About Informa Markets
Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Engineering, Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and, do business through face-to-face exhibitions, specialist digital content and, actionable data solutions. As the world's leading exhibitions organizer, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit www.informamarkets.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210427005048/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom